Sucampo Pharma (SCMP) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Guggenheim Reiterates Buy on Sucampo Pharma (SCMP) Following 1Q Earnings
May 4, 2016 1:07 PM EDTGuggenheim reiterated a Buy rating and $29.00 price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) following the company's 1Q earnings report. SCMP reported 1Q16 diluted EPS of $0.21, in line with consensus. Management reiterated its '16 adjusted EPS guidance of $1.02 at the midpoint (consensus was $1.05).
Analyst... More
